Recombinant Technologies
About this raise
Recombinant Technologies, with a pre-money valuation of $35 million, is raising crowdfunding on StartEngine. The company is developing a revolutionary treatment for Alzheimer’s Disease. It is designing a process of injecting a molecule into the patients to reduce the plaque buildup that causes dementia. Dr. Pazhani Sundaram founded Recombinant Technologies in May 2021. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000, and the proceeds will be used to complete the studies to get the FDA approval of the device. Recombinant Technologies’ patented technology was developed with $4.5 million in grants and has been shown to improve memory in mice.
Investment Overview
Invested : $98,143
Deal Terms
Total Commitments
- Platform
- StartEngine
- Start Date
- 07/15/2021
- Close Date
- 02/11/2022
$10,000
$1,070,000
$200
Equity - Common
Pre-Seed
RegCF
$1.00
$35,000,000
Company & Team
Company
- Year Founded
- 2021
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
| Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|
| 02/11/2022 | StartEngine | $35,000,000 | $98,143 | Equity - Common | Funded | RegCF |